Tripathi Richa, Reich Stephen G, Scorr Laura, Guardiani Elizabeth, Factor Stewart A
Department of Neurology Emory University School of Medicine Atlanta Georgia USA.
Department of Neurology University of Maryland School of Medicine Baltimore Maryland USA.
Mov Disord Clin Pract. 2019 Jul 24;6(7):601-604. doi: 10.1002/mdc3.12812. eCollection 2019 Sep.
Tardive syndrome (TS) is an often irreversible movement disorder caused by dopamine receptor-blocking agents (DRBAs). Although TS are well recognized to occur with typical antipsychotics, less well appreciated is that atypical antipsychotics also carry a risk of TS.
Case series.
We describe 4 patients who developed tardive dystonia, tardive akathisia, and drug-induced parkinsonism with the use of the atypical antipsychotic, lurasidone, which was U.S. Food and Drug Administration approved in 2013 for use in bipolar disorder and schizophrenia.
Movement disorders are reported as a rare side effect of lurasidone, and, as such, prescribers may perceive a false sense of security regarding this potential complication. Our cases indicate that this relatively new atypical antipsychotic may cause irreversible disabling TS as well as parkinsonism. Caution must be taken when prescribing lurasidone.
迟发性综合征（TS）是一种常由多巴胺受体阻滞剂（DRBAs）引起的不可逆运动障碍。虽然TS与典型抗精神病药物一同出现已广为人知，但非典型抗精神病药物也存在引发TS的风险这一点却鲜为人知。
病例系列研究。
我们描述了4例使用非典型抗精神病药物鲁拉西酮后出现迟发性肌张力障碍、迟发性静坐不能和药物性帕金森综合征的患者。鲁拉西酮于2013年被美国食品药品监督管理局批准用于双相情感障碍和精神分裂症。
运动障碍被报告为鲁拉西酮的一种罕见副作用，因此，处方医生可能会对这种潜在并发症产生一种错误的安全感。我们的病例表明，这种相对较新的非典型抗精神病药物可能会导致不可逆的致残性TS以及帕金森综合征。开具鲁拉西酮处方时必须谨慎。
